Sortilin levels correlate with major cardiovascular events of diabetic patients with peripheral artery disease following revascularization: a prospective study

  • Federico Biscetti (Creator)
  • Elisabetta Nardella (Creator)
  • Maria Margherita Rando (Creator)
  • Andrea Leonardo Cecchini (Creator)
  • Nicola Bonadia (Creator)
  • Piergiorgio Bruno (Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Cardiac Surgery Unit) (Creator)
  • Flavia Angelini (Creator)
  • Carmine Di Stasi (Contributor)
  • Andrea Contegiacomo (Creator)
  • Angelo Santoliquido (Creator)
  • Dario Pitocco (Creator)
  • Raffaele Landolfi (Medical Vascular Disease Clinic Unit, Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli IRCCS) (Creator)
  • Andrea Flex (Creator)

Dataset

Description

Abstract Background Peripheral artery disease (PAD) represents one of the most relevant vascular complications of type 2 diabetes mellitus (T2DM). Moreover, T2DM patients suffering from PAD have an increased risk of major adverse cardiovascular events (MACE) and major adverse limb events (MALE). Sortilin, a protein involved in apolipoproteins trafficking, is associated with lower limb PAD in T2DM patients. Objective To evaluate the relationship between baseline serum levels of sortilin, MACE and MALE occurrence after revascularization of T2DM patients with PAD and chronic limb-threatening ischemia (CLTI). Research design and methods We performed a prospective non-randomized study including 230 statin-free T2DM patients with PAD and CLTI. Sortilin levels were measured before the endovascular intervention and incident outcomes were assessed during a 12 month follow-up. Results Sortilin levels were significantly increased in individuals with more aggressive PAD (2.25 ± 0.51 ng/mL vs 1.44 ± 0.47 ng/mL, p
Dati resi disponibili2020
Editorefigshare

Cita questo